Gowling WLG advises AstraZeneca on cancer drug collaboration
Legal experts at the firm have played a pivotal role in assisting AstraZeneca and Merck & Co., Inc. formulate a global strategic oncology collaboration to develop and commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class inhibitor that is currently approved for the treatment of BRCA-mutated ovarian cancer. Gowling WLG acted […]